

Live Biotherapeutics Products and Microbe CDMO Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2018-2028 Segmented By Application (C.difficile, Crohns disease, IBS, Diabetes, and Others), By Product (APIs, FDFs), By Type of Formulation (Solid Formulations, Oral Liquids, Injectables, and Others), By Scale of Operation (Preclinical Scale Operations, Clinical Scale Operations, and Commercial Scale Operations), By Region and Competition

<https://marketpublishers.com/r/L810B3583844EN.html>

Date: October 2023

Pages: 177

Price: US\$ 4,900.00 (Single User License)

ID: L810B3583844EN

Abstracts

Global Live Biotherapeutics Products (LBPs) Market is anticipated to rise at a high CAGR during the forecast period, 2024-2028. Growing prevalence of certain chronic diseases such as cardiovascular diseases, diabetes, chronic respiratory diseases, cancer, and chronic kidney disease across various countries are expected to register a lucrative growth to global live biotherapeutics products and microbe CDMO market in the forecast period. Moreover, growing preference of people around the world towards personalized medicines for physical and mental health are expected to propel the growth of live biotherapeutics products and microbe CDMO market in upcoming years.

Live Biotherapeutics Products (LBPs) are a type of therapeutic product that utilize living microbes to treat various medical conditions. Some of the commonly available live biotherapeutics products available in the market includes Lactobacillus acidophilus, Bifidobacterium lactis, Streptococcus thermophilus, Saccharomyces boulardii, and Escherichia coli Nissle. These microbes, such as bacteria or yeast, are typically found in

the gut microbiome and play a critical role in maintaining human health. LBPs work by introducing these microbes into the body in a controlled manner to restore or enhance their function.

A Microbial Contract Development and Manufacturing Organization (CDMO) is a company that specializes in the development and manufacturing of microbial-based products, including live biotherapeutics product. Microbe CDMOs can provide a range of services, including strain development, fermentation optimization, downstream processing, and quality control. CDMO activities can be broadly categorized into three categories such as product development, manufacture of active pharmaceutical ingredients (API), and manufacture of finished dosage forms (FDF). There are around 500 Contract Development and Manufacturing Organization established in the world. Among them, Switzerland-based Lonza is the leading CDMO industry functioning across the world.

Increasing Prevalence of Chronic Diseases

Chronic diseases are defined broadly as conditions that progress slowly and persist over an extended period. Some of the major risk factors which lead to the development of chronic illness inside human body include intake of unbalanced diet, consumption of alcohol, smoking cigarettes, physical inactivity, and others. Cardiovascular diseases, Cancer, and diabetes are three most prevailing chronic diseases in the world which are thereby increasing the mortality of every country in the forecast period. According to the report published by Pan American Health Organization (PAHO) in 2019, Ischemic heart disease accounted for 73.6 deaths per 100,000 population in the world, followed by stroke with 32.3 deaths, other circulatory diseases with 14.8 deaths, hypersensitive heart disease with 10.6 deaths, cardiomyopathy, myocarditis, and endocarditis with 5.1 deaths and rheumatic heart disease with 0.7 deaths of total population across the world. After cardiovascular diseases, cancer has been reported as second major reason behind the growing mortality rate of various developing countries across the world. As per the report published by World Health Organization (WHO) in 2022, it has been observed that lung cancer has been the most prominent type of cancer prevailing across the world accounting for 1.80 million deaths, followed by 9,16,000 deaths caused by colon and rectum cancer, 8,30,000 deaths due to liver cancer, 7,69,000 deaths by stomach cancer and 6,85,000 deaths caused by breast cancer. Live biotherapeutic products are designed to modulate the gut microbiome which plays a major role in maintaining a healthy immune system and preventing chronic diseases. Moreover, microbe CDMOs provide customized solutions for the development, manufacturing, and scale-up of microbial products for clinical trials and commercial use. Other health

problems which can affect the human body along with prevalence of chronic diseases are expected to propel the growth of global biotherapeutics products and microbe CDMO market in the forecast period.

Rise in Demand for Personalized Medicines

The growing demand for personalized medicines is indeed a significant driver of the global biotherapeutics products and microbe CDMO (Contract Development and Manufacturing Organization) market. Biotherapeutics products, including personalized medicines, are a major growth area of pharmaceutical industry. These products are derived from biological sources, such as living cells, and can be used to treat a wide range of diseases, including cancer, autoimmune disorders, and genetic diseases. Moreover, microbe CDMOs are specialized in the development and manufacturing of biotherapeutics products, including personalized medicines, using microbial systems such as bacteria, yeast, and fungi. These CDMOs offer a range of services, including cell line development, process development, analytical development, and manufacturing. The growing demand for personalized medicines has led to an increase in the demand for these services which are further projected to register an impressive growth to Global Biotherapeutics Products and Microbe CDMO market in upcoming years.

Market Segmentation

Global live biotherapeutics products and microbe CDMO market is segmented based on application, product, type of formulation, scale of operation, company, and region. In terms of application, the live biotherapeutics products and microbe CDMO market is categorized into C.difficile, Crohns disease, IBS, diabetes, and others. Based on product, the global live biotherapeutics products and microbe CDMO market is fragmented into APIs and FDFs. Based on type of formulation, the market is segmented into solid formulations, oral liquids, injectables, and others. Based on scale of operation, the global live biotherapeutics products and microbe CDMO market is fragmented into preclinical scale operations, clinical scale operations, and commercial scale operations.

Market Players

Arranta Bio Holdings LLC., 4D Pharma plc., Cerbios-Pharma S.A., Biose Industrie, Assembly Biosciences, Inc., Wacker Chemie AG, Quay Pharmaceuticals Ltd., Bacthera AG, LONZA, and Inpac Probiotics are the major players of global live biotherapeutics products and microbe CDMO market.

Report Scope:

In this report, Global Live Biotherapeutics Products and Microbe CDMO Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Live Biotherapeutics Products and Microbe CDMO Market, By Application:

C.difficile

Crohns disease

IBS

Diabetes

Others

Live Biotherapeutics Products and Microbe CDMO Market, By Product:

APIs

FDFs

Live Biotherapeutics Products and Microbe CDMO Market, By Type of Formulation:

Solid Formulations

Oral Liquids

Injectables

Others

Live Biotherapeutics Products and Microbe CDMO Market, By Scale of Operation:

Preclinical Scale Operations

Clinical Scale Operations

Commercial Scale Operations

Live Biotherapeutics Products and Microbe CDMO Market, By region:

North America

United States

Canada

Mexico

Asia-Pacific

China

India

South Korea

Australia

Japan

Europe

Germany

France

United Kingdom

Spain

Italy

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Live Biotherapeutics Products and Microbe CDMO Market

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. GLOBAL LIVE BIOTHERAPEUTICS PRODUCTS AND MICROBE CDMO MARKET OUTLOOK

- 5.1. Market Size & Forecast
 - 5.1.1. By Value & Volume
- 5.2. Market Share & Forecast
 - 5.2.1. By Application (C.difficile, Crohns disease, IBS, Diabetes, Others)
 - 5.2.2. By Product (APIs, FDFs)
 - 5.2.3. By Type of Formulation (Solid Formulations, Oral Liquids, Injectables, Others)

5.2.4. By Scale of Operation (Preclinical Scale Operations, Clinical Scale Operations, Commercial Scale Operations)

5.2.5. By Region

5.2.6. By Company (2022)

5.3. Product Market Map

6. NORTH AMERICA LIVE BIOTHERAPEUTICS PRODUCTS AND MICROBE CDMO MARKET OUTLOOK

6.1. Market Size & Forecast

6.1.1. By Value & Volume

6.2. Market Share & Forecast

6.2.1. By Application

6.2.2. By Product

6.2.3. By Type of Formulation

6.2.4. By Scale of Operation

6.2.5. By Country

6.3. North America: Country Analysis

6.3.1. United States Live Biotherapeutics Products and Microbe CDMO Market Outlook

6.3.1.1. Market Size & Forecast

6.3.1.1.1. By Value & Volume

6.3.1.2. Market Share & Forecast

6.3.1.2.1. By Application

6.3.1.2.2. By Product

6.3.1.2.3. By Type of Formulation

6.3.1.2.4. By Scale of operation

6.3.2. Mexico Live Biotherapeutics Products and Microbe CDMO Market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1. By Value & Volume

6.3.2.2. Market Share & Forecast

6.3.2.2.1. By Application

6.3.2.2.2. By Product

6.3.2.2.3. By Type of Formulation

6.3.2.2.4. By Scale of Operation

6.3.3. Canada Live Biotherapeutics Products and Microbe CDMO Market Outlook

6.3.3.1. Market Size & Forecast

6.3.3.1.1. By Value & Volume

6.3.3.2. Market Share & Forecast

- 6.3.3.2.1. By Application
- 6.3.3.2.2. By Product
- 6.3.3.2.3. By Type of Formulation
- 6.3.3.2.4. By Scale of Operation

7. EUROPE LIVE BIOTHERAPEUTICS PRODUCTS AND MICROBE CDMO MARKET OUTLOOK

7.1. Market Size & Forecast

- 7.1.1. By Value & Volume

7.2. Market Share & Forecast

- 7.2.1. By Application
- 7.2.2. By Product
- 7.2.3. By Type of Formulation
- 7.2.4. By Scale of Operation

7.3 Europe: Country Analysis

7.3.1. France Live Biotherapeutics Products and Microbe CDMO Market Outlook

- 7.3.1.1. Market Size & Forecast
 - 7.3.1.1.1. By Value & Volume
- 7.3.1.2. Market Share & Forecast
 - 7.3.1.2.1. By Application
 - 7.3.1.2.2. By Product
 - 7.3.1.2.3. By Type of Formulation
 - 7.3.1.2.4. By Scale of Operation

7.3.2. Germany Live Biotherapeutics Products and Microbe CDMO Market Outlook

- 7.3.2.1. Market Size & Forecast
 - 7.3.2.1.1. By Value & Volume
- 7.3.2.2. Market Share & Forecast
 - 7.3.2.2.1. By Application
 - 7.3.2.2.2. By Product
 - 7.3.2.2.3. By Type of Formulation
 - 7.3.2.2.4. By Scale of Operation

7.3.3. United Kingdom Live Biotherapeutics Products and Microbe CDMO Market Outlook

- 7.3.3.1. Market Size & Forecast
 - 7.3.3.1.1. By Value & Volume
- 7.3.3.2. Market Share & Forecast
 - 7.3.3.2.1. By Application
 - 7.3.3.2.2. By Product

- 7.3.3.2.3. By Type of Formulation
- 7.3.3.2.4. By Scale of Operation
- 7.3.4. Italy Live Biotherapeutics Products and Microbe CDMO Market Outlook
 - 7.3.4.1. Market Size & Forecast
 - 7.3.4.1.1. By Value & Volume
 - 7.3.4.2. Market Share & Forecast
 - 7.3.4.2.1. By Application
 - 7.3.4.2.2. By Product
 - 7.3.4.2.3. By Type of Formulation
 - 7.3.4.2.4. By Scale of Operation
- 7.3.5. Spain Live Biotherapeutics Products and Microbe CDMO Market Outlook
 - 7.3.5.1. Market Size & Forecast
 - 7.3.5.1.1. By Value & Volume
 - 7.3.5.2. Market Share & Forecast
 - 7.3.5.2.1. By Application
 - 7.3.5.2.2. By Product
 - 7.3.5.2.3. By Type of Formulation
 - 7.3.5.2.4. By Scale of Operation

8. ASIA-PACIFIC LIVE BIOTHERAPEUTICS PRODUCTS AND MICROBE CDMO MARKET OUTLOOK

- 8.1. Market Size & Forecast
 - 8.1.1. By Value & Volume
- 8.2. Market Share & Forecast
 - 8.2.1. By Application
 - 8.2.2. By Product
 - 8.2.3. By Type of Formulation
 - 8.2.4. By Scale of Operation
 - 8.2.5. By Country
- 8.3. Asia-Pacific: Country Analysis
 - 8.3.1. China Live Biotherapeutics Products and Microbe CDMO Market Outlook
 - 8.3.1.1. Market Size & Forecast
 - 8.3.1.1.1. By Value & Volume
 - 8.3.1.2. Market Share & Forecast
 - 8.3.1.2.1. By Application
 - 8.3.1.2.2. By Product
 - 8.3.1.2.3. By Type of Formulation
 - 8.3.1.2.4. By Scale of Operation

8.3.2. India Live Biotherapeutics Products and Microbe CDMO Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value & Volume

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Application

8.3.2.2.2. By Product

8.3.2.2.3. By Type of Formulation

8.3.2.2.4. By Scale of Operation

8.3.3. South Korea Live Biotherapeutics Products and Microbe CDMO Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value & Volume

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Application

8.3.3.2.2. By Product

8.3.3.2.3. By Type of Formulation

8.3.3.2.4. By Scale of Operation

8.3.4. Japan Live Biotherapeutics Products and Microbe CDMO Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value & Volume

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Application

8.3.4.2.2. By Product

8.3.4.2.3. By Type of Formulation

8.3.4.2.4. By Scale of Operation

8.3.5. Australia Live Biotherapeutics Products and Microbe CDMO Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value & Volume

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Application

8.3.5.2.2. By Product

8.3.5.2.3. By Type of Formulation

8.3.5.2.4. By Scale of Operation

9. SOUTH AMERICA LIVE BIOTHERAPEUTICS PRODUCTS AND MICROBE CDMO MARKET OUTLOOK

9.1. Market Size & Forecast

9.1.1. By Value & Volume

9.2. Market Share & Forecast

- 9.2.1. By Application
- 9.2.2. By Product
- 9.2.3. By Type of Formulation
- 9.2.4. By Scale of Operation
- 9.2.5. By Country
- 9.3. South America: Country Analysis
 - 9.3.1. Brazil Live Biotherapeutics Products and Microbe CDMO Market Outlook
 - 9.3.1.1. Market Size & Forecast
 - 9.3.1.1.1. By Value & Volume
 - 9.3.1.2. Market Share & Forecast
 - 9.3.1.2.1. By Application
 - 9.3.1.2.2. By Product
 - 9.3.1.2.3. By Type of Formulation
 - 9.3.1.2.4. BY Scale of Operation
 - 9.3.2. Argentina Live Biotherapeutics Products and Microbe CDMO Market Outlook
 - 9.3.2.1. Market Size & Forecast
 - 9.3.2.1.1. By Value & Volume
 - 9.3.2.2. Market Share & Forecast
 - 9.3.2.2.1. By Application
 - 9.3.2.2.2. By Product
 - 9.3.2.2.3. By Type of Formulation
 - 9.3.2.2.4. By Scale of Operation
 - 9.3.3. Colombia Live Biotherapeutics Products and Microbe CDMO Market Outlook
 - 9.3.3.1. Market Size & Forecast
 - 9.3.3.1.1. By Value & Volume
 - 9.3.3.2. Market Share & Forecast
 - 9.3.3.2.1. By Application
 - 9.3.3.2.2. By Product
 - 9.3.3.2.3. By Type of Formulation
 - 9.3.3.2.4. By Scale of Operation

10. MIDDLE EAST AND AFRICA LIVE BIOTHERAPEUTICS PRODUCTS AND MICROBE CDMO MARKET OUTLOOK

- 10.1. Market Size & Forecast
 - 10.1.1. By Value & Volume
- 10.2. Market Share & Forecast
 - 10.2.1. By Application
 - 10.2.2. By Product

- 10.2.3. By Type of Formulation
- 10.2.4. By Scale of Operation
- 10.2.5. By Country
- 10.3. MEA: Country Analysis
 - 10.3.1. South Africa Live Biotherapeutics Products and Microbe CDMO Market Outlook
 - 10.3.1.1. Market Size & Forecast
 - 10.3.1.1.1. By Value & Volume
 - 10.3.1.2. Market Share & Forecast
 - 10.3.1.2.1. By Application
 - 10.3.1.2.2. By Product
 - 10.3.1.2.3. By Type of Formulation
 - 10.3.1.2.4. By Scale of Operation
 - 10.3.2. Saudi Arabia Live Biotherapeutics Products and Microbe CDMO Market Outlook
 - 10.3.2.1. Market Size & Forecast
 - 10.3.2.1.1. By Value & Volume
 - 10.3.2.2. Market Share & Forecast
 - 10.3.2.2.1. By Application
 - 10.3.2.2.2. By Product
 - 10.3.2.2.3. By Type of Formulation
 - 10.3.2.2.4. By Scale of Operation
 - 10.3.3. UAE Live Biotherapeutics Products and Microbe CDMO Market Outlook
 - 10.3.3.1. Market Size & Forecast
 - 10.3.3.1.1. By Value & Volume
 - 10.3.3.2. Market Share & Forecast
 - 10.3.3.2.1. By Application
 - 10.3.3.2.2. By Product
 - 10.3.3.2.3. By Type of Formulation
 - 10.3.3.2.4. By Scale of Operation

11. MARKET DYNAMICS

- 11.1. Drivers
- 11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

13. PESTLE ANALYSIS

14. PORTER'S FIVE FORCES ANALYSIS

- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Product

15. COMPETITIVE LANDSCAPE

- 15.1. Business Overview
- 15.2. Company Snapshot
- 15.3. Products & Services
- 15.4. Financials (In case of listed companies)
- 15.5. Recent Developments
- 15.6. SWOT Analysis
 - 15.6.1. Arranta Bio Holdings LLC.
 - 15.6.2. 4D Pharma plc.
 - 15.6.3. Cerbios-Pharma S.A.
 - 15.6.4. Biose Industrie
 - 15.6.5. Assembly Biosciences, Inc.
 - 15.6.6. Wacker Chemie AG
 - 15.6.7. Quay Pharmaceuticals Ltd.
 - 15.6.8. Bacthera AG
 - 15.6.9. LONZA
 - 15.6.10. Inpac Probiotics

16. STRATEGIC RECOMMENDATIONS

17. ABOUT US & DISCLAIMER

I would like to order

Product name: Live Biotherapeutics Products and Microbe CDMO Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2018-2028 Segmented By Application (C.difficile, Crohns disease, IBS, Diabetes, and Others), By Product (APIs, FDFs), By Type of Formulation (Solid Formulations, Oral Liquids, Injectables, and Others), By Scale of Operation (Preclinical Scale Operations, Clinical Scale Operations, and Commercial Scale Operations), By Region and Competition

Product link: <https://marketpublishers.com/r/L810B3583844EN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/L810B3583844EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms

& Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970